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Galectin-8 (Gal-8) is a tandem-repeat type galectin with affinity for β-galactosides,
bearing two carbohydrate recognition domains (CRD) connected by a linker peptide. The
N- and C-terminal domains (Gal-8N and Gal-8C) share 35% homology, and their glycan
ligand specificity is notably dissimilar: while Gal-8N shows strong affinity for α(2-3)-sialy-
lated oligosaccharides, Gal-8C has higher affinity for non-sialylated oligosaccharides,
including poly-N-acetyllactosamine and/ or A and B blood group structures. Particularly
relevant for understanding the biological role of this lectin, full-length Gal-8 can bind cell
surface glycoconjugates with broader affinity than the isolated Gal-8N and Gal-8C
domains, a trait also described for other tandem-repeat galectins. Herein, we aim to
discuss the potential use of separate CRDs in modelling tandem-repeat galectin-8 and its
biological functions. For this purpose, we will cover several aspects of the structure–func-
tion relationship of this protein including crystallographic structures, glycan specificity,
cell function and biological roles, with the ultimate goal of understanding the potential
role of each CRD in predicting full-length Gal-8 involvement in relevant biological
processes.
Introduction
The galectin family is a group of evolutionary-conserved soluble lectins characterized by their ability
to recognize β-galactosides through their carbohydrate recognition domains (CRDs) [1–5]. Current
classification of these lectins relies on their structure and number of CRDs; thus, prototype galectins
(Gal-1, -2, -7) present only one CRD, while chimera type Gal-3 has a single CRD and a non-lectin
N-terminal domain. In turn, tandem-repeat type galectins such as Gal-4, -8, -9 and -12 are composed
by an N-terminal and a C-terminal CRD, linked by a peptidic sequence of variable length [6].
Synthesized in the cytosol and with a still unknown non-classical secretion pathway, galectins
display an army of intracellular and extracellular functions [7,8]. In the extracellular compartment,
and due to the bivalent nature of tandem-repeat type and oligomerization of prototype and chimera
types, galectins are able to cross-link glycosylated receptors on the cell surface forming supramolecular
structures often termed ‘lattices’ [9,10], that convey glycan-containing information into distinct signal-
ing programs and control cell fate [11]. Interestingly, galectins regulate glycoprotein uptake by indu-
cing their cross-linking into lattices avoiding internalization [12], or by co-clustering them with
glycolipids into raft-type membrane nanodomains called clathrin-independent carriers (CLICs) indu-
cing endocytosis in a process termed glycolipid–lectin (GL-Lect) hypothesis [13,14]. It should be
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noted that carbohydrate-mediated interactions of galectins with glycoproteins and glycolipids seem to induce
mild cluster glycoside effects in spite of the presence of multivalent glycan epitopes [2,15]. Moreover, galectin–
protein interactions are also acquiring significant relevance [2,16].
The human Gal-8 gene (LGALS8) was shown to encode six different isoforms resulting from alternative spli-
cing [17–19]; three of these isoforms are tandem-repeat type, which have been named according to the length
of the linker peptide as: Gal-8S (‘small’), Gal-8M (‘medium’) or Gal-8L (‘long’). The other Gal-8 isoforms are
isolated CRDs that have been only found at the transcription but not protein level [20,21]. Gal-8 N- and
C-terminal domains (Gal-8N and Gal-8C, respectively) share 35% homology, and their sequence motifs are
conserved among most galectin members (Figure 1) [17,25]. Recombinant expression of each separate CRD
showed that Gal-8N exhibits strong affinity for α(2-3)-sialylated and 30-sulfated oligosaccharides [26,27]. In
contrast, Gal-8C exhibits preferential binding for non-sialylated oligosaccharides, including
poly-N-acetyllactosamine ([-3)Galβ(1-4)GlcNAcβ(1-]n, poly-LacNAc) and A and B blood group antigens
[23,28]. However, the reported glycan preferences of full-length Gal-8 do not necessarily reflect the binding
preferences of each of its CRDs, showing a broader glycan recognition pattern and tight binding to ligands that
present moderate or weak affinity for each separate CRD [29]. In the next sections, we discuss available data on
Gal-8 glycan specificity, comparing the full-length lectin to its separate N-CRD and C-CRD domains, and
interpret these results from a crystallographic perspective. Finally, we analyze how this particular glycan specifi-
city impacts on cell binding and key biological functions.
Gal-8 carbohydrate-binding specificity is not solely dictated
by its separate CRDs
Isolated Gal-8 CRDs differ noticeably in their carbohydrate specificity [26,27]. As a general trend, Gal-8N pref-
erentially binds α(2-3)-sialylated oligosaccharides, while Gal-8C binds neutral β-galactosidic glycans with
higher affinity. Indeed, frontal affinity chromatography (FAC) studies showed preferential binding of Gal-8N to
α(2-3)-sialylated oligosaccharides (i.e. 30-sialyllactose, Kd = 0.62 × 10
−6 M for Gal-8N; Kd = 97 × 10
−6 M for
Gal-8C) [26]. Compared with Gal-8C, the N-terminal domain has lower affinity for different branched
complex N-glycans (Kd = 47–290 × 10
−6 M for Gal-8N; Kd = 26–52 × 10
−6 M for Gal-8C). Surface plasmon res-
onance (SPR) validated these results for Gal-8N, with high affinity for 30-sialyllactose (30-SLac), and also
demonstrated preferential recognition of 30-sulfated and Lewis X-containing glycans than for oligosaccharides
bearing terminal type I (Galβ(1-3)GlcNAc) or type II (Galβ(1-4)GlcNAc) LacNAc [27]. Conversely, Gal-8C
Figure 1. Sequence alignment of selected galectin family members.
Sequences were aligned using Jalview software [22]. Each carbohydrate recognition domain (CRD) consists of 135–165 amino
acids, arranged on two antiparallel β-sheets, each composed of six (F0–F5 and S1–S6) β-strands. Identical residues of galectins
are highlighted in blue and similar residues in light blue. Tandem-repeat type galectins are composed of two non-identical
CRDs, joined by a hinge region. Gal-8 highly conserved residues shared with the galectin family, essential for protein–
carbohydrate interactions, are highlighted in red. Key Gal-8 residues for glycan recognition (not usually found in galectins) are
depicted in orange. Amino acids pointed out by crystallization studies as relevant for glycan complexes [23,24] are numerated.
© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society2
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preferentially bound non-sialylated oligosaccharides like poly-LacNAc and blood group A (BGA; GalNAcα
(1-3)[Fucα(1-2)]Galβ(1-4)GlcNAc) and B (BGB; Galα(1-3)[Fucα(1-2)]Galβ(1-4)GlcNAc) determinants [23].
Notably, glycan array studies narrowed down the preferred ligands for Gal-8N to 30-sialylated/sulfated Galβ
(1-4)Glc (lactose, Lac), type I LacNAc or Galβ(1-3)GalNAc (Thomsen-Friedenreich antigen, TF antigen),
whereas type II LacNAc was less preferred [29]. Contrariwise, oligosaccharides containing poly-LacNAc or A
and B blood group determinants were preferential ligands for Gal-8C [29,30]. Accordingly, sialylation signifi-
cantly inhibited Gal-8C binding to poly-LacNAc structures [30]. Consistent with these experimental studies,
computational analysis by molecular dynamic simulations showed that Gal-8C presented the strongest binding
energy for lacto-N-neotetraose (Galβ(1-4)GlcNAcβ(1-3)Galβ(1-4)Glc), followed by diLacNAc (Galβ(1-4)
GlcNAcβ(1-3)Galβ(1-4)GlcNAc), A and B blood group antigens, and, finally, type I and II LacNAc and Lac
[31].
When comparing full-length Gal-8 to each isolated CRD, glycan microarray studies showed that Gal-8
binding pattern was dominated by the N-terminal domain, with 30-sulfated and 30-sialylated glycans as prefer-
ential ligands [30]. Moreover, glycan arrays demonstrated that isoform Gal-8S recognizes a broader scope of
oligosaccharides, further beyond the sum of structures bound by each domain. For example, recognition of
glycans presenting -at least- two Lac, or type I or type II LacNAc moieties seemed to be mediated by the com-
bined binding of the two CRDs, even if the affinity for each isolated CRD was too weak to be detected on the
array [29]. In other glycan microarray studies, when evaluated at low concentrations, Gal-8N and full-length
Gal-8 recognized the same 30-sulfated and 30-sialylated glycans with similar relative affinity [30]. In contrast, as
previously observed, Gal-8C recognized poly-LacNAc and blood group antigens, while it exhibited no binding
towards sulfated or sialylated glycans. Furthermore, sialylation significantly inhibited Gal-8C binding to
poly-LacNAc structures [30].
Fluorescence anisotropy results, obtained with full-length Gal-8, isolated CRDs and ligands in solution, were
consistent with glycan arrays and SPR data: the best ligand for Gal-8N was 30-sialyllactose with Kd = 53 ×
10−9M [29]. Inhibition experiments confirmed similar Kd values for 30-sialylated Galβ(1-3)GlcNAc and Galβ
(1-3)GalNAc [29]. In each case, Gal-8N bound the 30-sialylated compound 100-fold stronger than the non-
sialylated disaccharide. On the other hand, and consistent with FAC measurements, Gal-8C affinities were in
general weaker than for Gal-8N, showing Kd values of 10–100 mM for most probes. Furthermore, binding to
Gal-8C was inhibited by 30-sialylated structures but enhanced by Galα(1-3) (Kd = 15.5 × 10
−6 M) or GalNAcα
(1-3)[Fucα(1-2)] (Kd = 8.8 × 10
−6 M) structures, validating previous data for BGA and BGB structures [29].
In summary, full-length Gal-8 binding preferences in solution were mainly dictated by the overall stronger
affinity of the N-terminal CRD. However, the dominance of the N-terminal domain in dictating affinity is not
complete, as full-length Gal-8 was able to recognize structures such as blood group A tetrasaccharide
(GalNAcα(1-3)[Fucα(1-2)]Galβ(1-4)Glc) with comparable affinity to the C-terminal CRD [29].
Crystallization studies
Gal-8N crystal structure
To understand the main interactions driving glycan affinity, Gal-8N complexes with Lac, 30-SLac and
30-sulfolactose were crystallized [23]. First, in the Gal-8N/Lac complex (Figure 2A), the β-galactoside moiety is
deeply buried in the binding site formed by β strands S4–S6, where Arg45, His65, Asn67, Arg69, Asn79 and Glu89
directly interact with Lac via hydrogen bond interactions (Table 1). In addition, Trp86 presents hydrophobic
interactions with the α-face of the galactose ring. Moreover, Gln47, Arg59 and Trp86 form water-mediated
hydrogen bond interactions with the Lac moiety (Table 1) [26].
Regarding the Gal-8N/30-sulfolactose complex, the residues involved in lactose moiety recognition are identi-
cal with those found in the Gal-8N/Lac complex. Additionally, four of these residues are also involved in
sulfate group recognition, namely Arg45, Gln47, Arg59 and Trp86 (Table 1). Of the three oxygen atoms present
in sulfate group, O2S and O3S present a direct hydrogen bond with the lectin: O3S forms hydrogen bonds
with Arg45, Gln47 and Arg59, whereas O2S only presents a hydrogen bond with Arg59. In addition, Trp86 inter-
acts with O2S through water-mediated hydrogen bonds (Table 1).
When comparing Gal-8N/30-SLac complex (Figure 2B) and Gal-8N/Lac complex (Figure 2A), the residues
involved in lactose recognition are the same. Moreover, the Gal-8N residues responsible for sialic acid recogni-
tion are those involved in sulfate group recognition in the Gal-8N/30-sulfolactose complex previously men-
tioned [23]. Indeed, the carboxylate group of sialic acid forms direct hydrogen bonds with Gln47, Arg59 and
© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society 3
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Trp86 (Table 1). Of these, Arg59 forms two independent hydrogen bonds including the shortest one, suggesting
that Arg59 is the key residue for sialic acid recognition. Additionally, Gln47 forms a water-mediated hydrogen
bond with the O4 oxygen atom of the sialic acid moiety [23]. Furthermore, site-directed mutagenesis followed
by SPR studies showed that in Gal-8N, Arg45, Gln47 and Arg59 are essential, and coordinately contribute to the
strong binding to 30-sialylated and 30-sulfated oligosaccharides, with Arg59 as the most critical residue (Figures
1, 2B) [23,27]. When comparing with other tandem-repeat type galectins, Arg59 is only found in Gal-8N and
Gal-12N [32].
Gal-8 N-CRD in complex with 30-sialyllactosamine [24] showed a very similar structure to the Gal-8N/30-SLac
complex previously described [23]: efficient salt bridge interactions are achieved between Arg59 side chain, located
in the long S3–S4 loop particular to Gal-8N (Figure 1) and the carboxyl group of the sialic acid; Gln47 and Trp86
also interact with the carboxyl group from both sides via hydrogen bonds [24], and Gal-O3 further contributes to
recognition of this moiety via hydrogen bonds with Arg45 and Gln47. Notably, Arg45 is also present in Gal-4N,
Gal-9N/C and Gal-12N (Figure 1), which have also shown significant affinity for α(2-3)-sialylated oligosacchar-
ides (Kd= 3.8–7.4 × 10
−6 M for Gal-9N, and Kd= 39–79 × 10
−6 M for Gal-9C) [26,32,33]. In addition, besides
tandem-repeat type galectins, Gal-3 also exhibits an arginine residue in the analogous position, namely Arg144,
and Salomonsson et al. [34] showed that Gal-3 R144S mutant exhibited lower affinity towards 30-sialylated oligo-
saccharides, further indicating the key role of this residue for sialic acid recognition.
Furthermore, while the N-acetyl group of the GlcNAc residue in 30-sialyllactosamine forms a water-mediated
hydrogen bond with Gal-8N Glu89, its O3 forms two direct hydrogen bonds with Arg69 and Glu89. The galact-
ose residue plays a key role: direct hydrogen bonds are found between Gal-O4 and His65, Asn67, and Arg69.
Moreover, four additional hydrogen bonds (O3-Arg45, O5-Arg69, O6-Asn79 and O6-Glu89) define the ligand
position. These amino acids, with the exception of Arg45, are strictly conserved among the galectin family
members and are essential for LacNAc recognition.
In conclusion, considering Gal-8N glycan interactions, structural complexes show that Arg59 is the critical
residue responsible for the strong affinity towards α(2-3)-sialylated oligosaccharides, while Arg45 and Gln47 are
also important in sialic acid moiety recognition [24].
Gal-8C crystal structure
Notably, and in contrast with Gal-8N, there are very few structural studies with the isolated Gal-8 C-terminal
domain, and none of them reports Gal-8C in complex with glycans. Structure of Gal-8C CRD was initially
reported by Tomizawa and co-workers using nuclear magnetic resonance (NMR) studies (PDB entry: 2YRO),
and in 2011, Zhou et al. described the crystal structure of apo Gal-8C (PDB entry: 3OJB), but none of these
studies were published. Finally, Li et al. elucidated the crystal structure of Gal-8 C-CRD in complex with a
Figure 2. Human Gal-8 CRDs structure in complex with glycans.
Crystal structures of: (A) Gal-8N/lactose complex [23]; (B) Gal-8N/30-sialyllactose complex [23]; (C) Gal-8C/lactose complex
[24]. Homologous amino acid residues in A, B and C are identically coloured according to their sequence alignment.
© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society4
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Table 1. Amino acid residues involved in Gal-8 glycan specificity, as determined by crystallographic
studies [23,24] Part 1 of 2
Crystal structure Amino acid CRD Interaction Glycan atom
Gal-8N/lactose Arg45 N-CRD H bond Gal-O3
Arg45 N-CRD H bond Gal-O4
Asn67 N-CRD H bond Gal-O4
Arg69 N-CRD H bond Gal-O4
His65 N-CRD H bond Gal-O4
Arg69 N-CRD H bond Gal-O5
Glu89 N-CRD H bond Gal-O5
Glu89 N-CRD H bond Gal-O6
Asn79 N-CRD H bond Gal-O6
Trp86 N-CRD Hydrophobic Gal α-face
Arg69 N-CRD H bond Glc-O3
Glu89 N-CRD H bond Glc-O3
Gln47 N-CRD H2O-mediated H bond Gal-O3
Trp86 N-CRD H2O-mediated H bond Gal-O3
Arg59 N-CRD H2O-mediated H bond Gal-O3
Gal-8N/30-sulfolactose Arg45 N-CRD H bond Gal-O3
Arg45 N-CRD H bond Gal-O4
Asn67 N-CRD H bond Gal-O4
Arg69 N-CRD H bond Gal-O4
His65 N-CRD H bond Gal-O4
Arg69 N-CRD H bond Gal-O5
Glu89 N-CRD H bond Gal-O5
Glu89 N-CRD H bond Gal-O6
Asn79 N-CRD H bond Gal-O6
Trp86 N-CRD Hydrophobic Gal α-face
Arg69 N-CRD H bond Glc-O3
Glu89 N-CRD H bond Glc-O3
Arg59 N-CRD H bond O2S
Arg45 N-CRD H bond O3S
Gln47 N-CRD H bond O3S
Arg59 N-CRD H bond O3S
Trp86 N-CRD H2O-mediated H bond O2S
Gal-8N/30-sialyllactose Arg45 N-CRD H bond Gal-O3
Arg45 N-CRD H bond Gal-O4
Asn67 N-CRD H bond Gal-O4
Arg69 N-CRD H bond Gal-O4
His65 N-CRD H bond Gal-O4
Arg69 N-CRD H bond Gal-O5
Glu89 N-CRD H bond Gal-O5
Glu89 N-CRD H bond Gal-O6
Asn79 N-CRD H bond Gal-O6
Trp86 N-CRD Hydrophobic Gal α-face
Arg69 N-CRD H bond Glc-O3
Glu89 N-CRD H bond Glc-O3
Gln47 N-CRD H bond Neu5Ac-O1
Arg59 N-CRD H bond Neu5Ac-O1
Trp86 N-CRD H bond Neu5Ac-O1
Gln47 N-CRD H2O-mediated H bond Neu5Ac-O4
Gal-8N/30-sialyllactosamine Arg45 N-CRD H bond Gal-O3
Arg45 N-CRD H bond Gal-O4
Asn67 N-CRD H bond Gal-O4
Arg69 N-CRD H bond Gal-O4
His65 N-CRD H bond Gal-O4
Arg69 N-CRD H bond Gal-O5
Glu89 N-CRD H bond Gal-O5
Glu89 N-CRD H bond Gal-O6
Asn79 N-CRD H bond Gal-O6
Continued
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peptide from the autophagy receptor named nuclear domain 10 protein 52 (NDP52), describing the first crys-
tallized protein–protein interaction for Gal-8 [35]. Gal-8 C-terminal domain adopted a bent β-sandwich struc-
tural fold formed by two antiparallel β-sheets of five and six strands, comprising the convex and concave
surfaces, respectively. In the crystallized structure, this NDP52 peptide bound to Gal-8 convex side, opposite to
the concave glycan-binding groove of the lectin [35,36].
Full-length Gal-8 crystal structure
The first X-ray structure of full-length Gal-8 was reported in 2012 by Yoshida et al. [24]. This work describes
the structure of Gal-8Null, a Gal-8 mutant in which the linker region was replaced by a His-Met dipeptide,
complexed with Lac (PDB entry: 3VKL) and 30-SLac (PDB entry: 3VKM). As expected, each CRD adopted a
β-sandwich arrangement formed by two antiparallel β-sheets of six (S1–S6) and five (F1–F5) β-strands, with a
short α-helix located between F5 and S2. Oligosaccharides bound to the concave surface created by S3, S4, S5
and S6 strands [24]. In addition, full-length Gal-8 structure complexed with NDP52 peptide was reported by
Kim et al. [36]. Although the structure of each CRD exhibited high correlation with the corresponding CRD
reported by Yoshida et al. [24], the superimposition of the full-length structure showed a large rotation of the
N-CRD relative to the C-CRD in the Gal-8–NDP52 complex. Different spatial orientation between the two
CRDs could be required for a specific biological function and may be a characteristic feature of tandem-repeat
type galectins [36].
The structure and glycan–lectin interactions of Gal-8N CRD observed in Gal-8Null complexes with Lac and
30-SLac [24] were almost identical as those described for the isolated Gal-8N/Lac and Gal-8N/30-SLac [23]
crystal structures (Supplementary Figure S1). In contrast with the N-CRD, in the C-CRD there are no residues
capable of sialic acid recognition: Arg59 is absent, and Arg45 and Gln47 are replaced by Ser213 and Asn215,
which explains the lack of sialic acid recognition by the C-terminal domain (Figure 1). The X-ray crystal struc-
ture of Gal-8C bound to Lac in Gal-8Null showed that galactose undergoes stacking interactions with Trp249,
and forms five hydrogen bonds with His229, Asn231, Arg233, Asn242 and Glu252 (Figure 2C) [24]. In addition,
glucose residue is recognized by hydrogen bonds from Arg233 and Glu252. Apart from the S3–S4 loop and
N-terminal region, superimposition of the two Gal-8 CRDs shows another structural difference at the S4–S5
loop, not related to ligand recognition: in the N-CRD, Lys71 and Arg72 direct their side chains toward the outer
side of the protein, possibly because of repulsion by the positively charged Arg45and Arg69, whereas Asn235 and
Ile236 in the C-CRD direct their side chains to the bound oligosaccharides [24]. In conclusion, and from a crys-
tallographic perspective, the main difference between the N- and C-terminal Gal-8 CRDs, determining their
Table 1. Amino acid residues involved in Gal-8 glycan specificity, as determined by crystallographic
studies [23,24] Part 2 of 2
Crystal structure Amino acid CRD Interaction Glycan atom
Trp86 N-CRD Hydrophobic Gal α-face
Gln47 N-CRD H bond Neu5Ac-O1
Arg59 N-CRD H bond Neu5Ac-O1
Trp86 N-CRD H bond Neu5Ac-O1
Arg69 N-CRD H bond GlcNAc-O3
Glu89 N-CRD H bond GlcNAc-O3
Glu89 N-CRD H bond GlcNAc-O7
Arg59 N-CRD Salt bridge Neu5Ac-O1
Gal-8C/lactose His229 C-CRD H bond Gal-O4
Asn231 C-CRD H bond Gal-O4
Arg233 C-CRD H bond Gal-O4
Arg233 C-CRD H bond Gal-O5
Asn242 C-CRD H bond Gal-O6
Glu252 C-CRD H bond Gal-O6
Glu252 C-CRD H bond Glc-O3
Arg233 C-CRD H bond Glc-O3
Trp249 N-CRD Hydrophobic Gal α-face
H bond: hydrogen bond. O2/3S: oxygen (2/3) in sulfate.
© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society6
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glycan-binding preferences, seems to be the presence of Arg59 residue in Gal-8N, essential for sialic acid and
sulfate groups recognition, which is replaced by Ser223 in Gal-8C [24].
From structure to biological activity: cell binding and
functional role of Gal-8
Upon secretion, Gal-8 acts as a matricellular protein capable of modulating cell adhesion and migration in
various cell types [37,38]. Gal-8 also promotes angiogenesis and lymphangiogenesis on vascular and lymphatic
endothelial cells, respectively, through interaction with a selected repertoire of glycosylated receptors [39,40]. In
addition, Gal-8 is up-regulated in several carcinomas [41,42], and can promote cell transformation in epithelial
cells, inducing enhanced cell migration, invasion, anchorage-independent growth and epithelial–mesenchymal
transition [43]. In vivo, Gal-8 is pro-tumorigenic in mouse xenografts [44,45], while high levels of circulating
Gal-8 have been detected in sera from breast, prostate and colon cancer patients [45–47].
In fact, the impact of specific Gal-8 CRDs–glycan interactions in the biological functions of the full-length
lectin is still matter of controversy [2,48]. Protein–protein interactions are crucial for Gal-8, and -although they
are beyond the focus of this review- noteworthy associations have been documented for: (i) actin [49]; (ii) a
peptide from NDP52, a pathogen-specific autophagy receptor which interacts with Gal-8C, inducing a selective
autophagy pathway against bacterial invasion [36,50,51]; and (iii) the farnesylated domain in the C-terminus of
the oncogene K-Ras4B, which binds to Gal-8 N-CRD modifying K-Ras-induced cell signalling [52].
In the next sections, we will cover interesting studies pointing out differences between Gal-8 CRDs on cell
binding in relation to their glycan specificities, and the promotion of some precise cell functions in which iso-
lated CRDs are compared with full-length Gal-8.
It should be pointed out that carbohydrate-binding studies for Gal-8 such as SPR, FAC, glycan array or
fluorescence anisotropy assays are usually performed at room temperature, while Gal-8 cell surface binding
(measured by flow cytometry) is assessed on ice (to avoid lectin internalization) and biological functions are
evaluated at 37°C.
Case study 1: HL60 promyelocytic leukemia cell desialylation did not alter
full-length Gal-8 binding: relevance of phosphatidylserine exposure and lectin
dimerization
Both recombinant Gal-8N and Gal-8C domains, as well as full-length Gal-8, bound to HL60 promyelocytic leu-
kemia cells (Table 2), but only full-length Gal-8 was able to elicit phosphatidylserine (PS) exposure, which
occurred independently of apoptosis [30]. As expected, treatment of HL60 cells with a pan-neuraminidase
increased Gal-8C binding, while reducing Gal-8N affinity. Moreover, enzymatic degradation of poly-LacNAc
glycans with endo-β-galactosidase reduced Gal-8C binding to HL60 cells, but did not alter Gal-8N interaction,
suggesting that poly-LacNAc recognition by full-length Gal-8 occurs through the C-terminal domain.
Importantly, cell desialylation did not alter full-length Gal-8 binding, but enhanced cellular sensitivity to
Gal-8-induced PS exposure, indicating that this function is mediated by Gal-8C [30].
Notably, dimerization of full-length Gal-8 at the HL60 cell surface was reported to occur through its
N-terminal domain, while isolated Gal-8N, but not Gal-8C, was also shown to form dimers [30]. Accordingly,
a recombinant Gal-8 variant (named Gal-8NM) with a mutated N-terminal domain inactive for glycan-binding
(R69H) and active Gal-8C also suffered dimerization, induced PS exposure and presented similar binding
towards poly-LacNAc glycans as full-length Gal-8. These results suggest that PS exposure is mediated by
Gal-8C but requires Gal-8 dimerization [30]. However, the identity of Gal-8N amino acids involved in lectin
dimerization is still uncertain.
Case study 2: Gal-8 binding to U937 monocytes and MOLT4 lymphoblastic
leukemia cells
In another relevant study, full-length Gal-8L and Gal-8S showed strong carbohydrate-dependent binding to
U937 monocytes and MOLT-4 lymphoblastic leukemia cells [29]. Since the preferred ligands for Gal-8N
contain α(2-3)-sialylated structures, the role of sialic acid at the cell surface was examined by digestion with a
pan-neuraminidase or with a specific α(2-3)-neuraminidase. As expected, both sialidase treatments reduced
Gal-8N binding (Table 2). Again, Gal-8C presented stronger binding to both neuraminidase-treated cells, in
© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society 7
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accordance to its glycan specificity, but notably, and similar to what was observed in HL60 cells, average
binding of full-length Gal-8 was not significantly altered after desialylation. These results indicate that non-
sialylated ligands provide sufficient affinity for cell binding of full-length Gal-8 [29].
Accordingly, Gal-8 Q47A mutant, with decreased affinity for α(2-3)-sialylated galactosides, did not present
significantly different binding to the cell surface compared with wild-type (WT) Gal-8. In summary, full-length
Gal-8 cell surface binding to U937 monocytes and MOLT4 lymphoblastic leukemia cells is mediated by both
CRDs [29].
Case study 3: CHO cells and glycosylation mutants as models for Gal-8
binding
Patnaik and co-workers exhaustively explored the contribution of each CRD using different CHO mutant cells
with altered glycosylation. Even though WT CHO cells present strong α(2-3)-sialylation, which is permissive
for Gal-8N [28,55], Gal-8 N-terminal domain bound weakly to WT CHO cells and, as expected, Gal-8C exhib-
ited low binding [28]. However, full-length Gal-8 was more efficient than any isolated CRD in CHO cell recog-
nition, even when considering different isoforms with either long or short inter-CRD linkers. Absence of
complex or hybrid N-glycans in Lec1 cells - which have a mutation in Mgat1 gene encoding for β
(1-2)-N-acetylglucosaminyltransferase I - (Figure 3) decreased full-length Gal-8 binding, while Gal-8N
showed similar binding to Lec1 and WT CHO cells. These results suggest that Gal-8N binding to Lec1 cells
could be mediated by recognition of gangliosides and sialylated O-glycans, while poor binding of full-length
Gal-8 is due to their high mannose N-glycans [28] (Figure 3). Accordingly, mutation in the CMP-sialic acid
transporter in Lec2 mutant CHO cells (Figure 3), which eliminates all sialic acid residues, hampered Gal-8N
binding, while full-length Gal-8 recognized these cells similar to WT cells [28] (Table 2), probably by inter-
action with Gal-8C.
Later, Nielsen et al. demonstrated the key role of sialic acid linkage in Gal-8 cell binding: as expected, CHO
cells lacking α(2-3)-sialylated complex N-glycans (deficient in sialyltransferases St3gal4/6) showed reduced
Table 2. Cell surface binding of full-length Gal-8, its separate CRDs or specific mutants





Non-treated (WT) ++++ ++ ++++ [30]
Pan-neuraminidase + ++++ ++++
U937 human monocyte cell line Non-treated (WT) ++ ++ ++++ Q47A* mutant:
++++
[29]
Pan-neuraminidase + +++ ++++
α(2-3)-neuraminidase + +++ ++++
CHO hamster ovary cell lines WT cells ++ + ++++ [28]
Lec2 − ++ +++
Lec1 ++ ND −








WT CHO cell line Non-treated (WT) ND ND +++ +++ (NN)** [54]
Pan-neuraminidase ND ND ++++ + (NN)**
MDA-MB-231 breast cancer cell
line
Non-treated (WT) ND ND +++ [45]
Pan-neuraminidase ND ND ++++
α(2-3)-neuraminidase ND ND ++++
WT: wild-type cell. KO: knocked-out cell. KI: knocked-in cell. ND: not determined.
*Full-length Gal-8, bearing a point mutation in glutamine47 substituted by alanine.
**Mutant chimera Gal-8, composed of two N-domains connected by a linker peptide.
© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society8
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binding of Gal-8N, and recognition was even lower after transfection with St6gal1 [53], a sialyltransferase
responsible for α(2-6)-sialylation, a non-permissive glycan modification for all members of the galectin family.
In WT CHO cells, Nielsen et al. [53] found higher binding of Gal-8N compared with Mgat1−/− cells, measured
either by fluorescence anisotropy or cell binding by flow cytometry [53], probably due to binding to oligo- or
poly-LacNAc structures present in WT cells, known to be good Gal-8N ligands [29]. On the contrary, Patnaik
et al. [28] showed similar Gal-8N binding in Lec1 and in WT CHO cells. We attribute these disparities ([53]
versus [28]) to different experimental approaches, but we certainly consider that the contribution of oligo- or
poly-LacNAc present in WT cells should promote Gal-8N binding as suggested in [53]. Furthermore, CHO
cells with only biantennary N-glycans (genetically engineered Mgat4A/4B/5−/− cells), possessing less branching
in complex N-glycans but normal sialylation in N- and O-glycans, showed higher Gal-8N binding than WT
cells, due to less antennarity and typical α(2-3)-sialylation [53]. In fact, Gal-8C also showed higher binding to
mutants with less branching in complex N-glycans than to WT CHO cells [53], suggesting that steric hindrance
between branches precludes access of C-CRD to internal poly-LacNAc [30].
Gal-8 is rapidly endocytosed at 37°C [56], as also demonstrated for other galectins [13,14,16].
Interestingly, in internalization experiments performed in CHO cells at 37°C, interaction of the N-CRD in
full-length Gal-8 with sialylated glycans has been shown to be crucial for lectin intracellular trafficking [56].
In fact, when comparing endocytosis of full-length Gal-8 in CHO cells and in Lec2 mutants, the pathway
after endocytosis differed dramatically. While in WT cells, Gal-8 was found along the plasma membrane,
near the nucleus and in small vesicles, in Lec2 cells, in contrast, Gal-8 was mainly found in larger vesicles
evenly spread in the cell [56]. Therefore, we might speculate that endocytic vesicles carrying full-length
Gal-8 could be involved in different intracellular routes and signalling pathways, depending on whether
their membranes contain sialylated saccharides or not. Similarly, cytosolic galectins were also shown to
modulate cellular responses according to the structure of cell surface glycans located in endocytic vesicles
Figure 3. Cell surface Gal-8 binding to CHO cells.
Binding of full-length Gal-8, Gal-8N and Gal-8C to different mutant and wild-type CHO cell lines is represented by: − (no
binding), and +(low binding) to ++++ (high binding). A schematic transmembrane glycoprotein is shown in green at CHO cell
surfaces, bearing N- and O-glycans. All sialic acids (Neu5Ac) in CHO cells are displaying α(2-3)-linkages. CHO cells
transfected with α(2-6)-sialyltransferase 1 (St6gal1 KI) exhibit α(2-6)-sialic acid in their N-glycans. St3gal4/6−/−: α
(2-3)-sialyltransferase deficient cells; Mgat−/−: N-acetylglucosaminyltransferase deficient cells; Lec1 cell: Mgat1 gene that
encodes β(1-2)-N-acetylglucosaminyltransferase I has been mutated; Lec2 cell: CMP-sialic acid transporter has been
mutated; WT: wild-type cell; KI: knocked-in cell; ND: not determined. Adapted from [28,53] and made in ©BioRender -
biorender.com.
© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society 9
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[57], which can be exposed to cytosolic galectins in damaged endosomes. Indeed, after experimental induc-
tion of vesicle damage, WT CHO cells expressing fluorescently-labelled Gal-8 showed large lectin aggre-
gates, co-localizing with carbohydrates in these endosomes, which finally generated Gal-8-mediated
autophagic activation. Conversely, in Lec2 cells, fewer lectin aggregates were observed compared with WT
cells, indicating that sialic acid contributes to Gal-8 effects [57]. In conclusion, cytosolic full-length Gal-8
preferentially binds to sialylated glycans on damaged endosomes, highlighting the key role of its N-CRD in
intracellular signalling [56].
When measuring adhesive capability of WT CHO cells to Gal-8-coated surfaces, the full-length lectin was
able to promote adhesion, with Gal-8N maintaining the properties of full-length Gal-8 when used at high con-
centrations; however, Gal-8C resulted functionally inactive. Importantly, deletion of the linker peptide partially
impaired Gal-8-mediated adhesive properties. Thus, linker flexibility and proper disposition of Gal-8 N- and
C-terminal domains are needed to mediate CHO cell adhesion [58].
Finally, Ludwig and colleagues engineered a homodimeric Gal-8 variant with two Gal-8N domains, named
Gal-8NN, and compared its cell binding to that of full-length WT Gal-8 (Table 2). In WT CHO cells with
abundant α(2-3)-sialylation, binding of Gal-8NN was found slightly reduced by desialylation compared with
non-treated cells, while the WT lectin showed enhanced staining of neuraminidase-treated versus control
cells [54].
Case study 4: Gal-8 mediates cell adhesion in desialylated breast cancer
MDA-MB-231 cells
Full-length Gal-8 induction of cell adhesion in MDA-MB-231 cells has been shown to be mediated by acti-
vated leukocyte cell adhesion molecule (ALCAM/CD166), a Gal-8 ligand [39,59]. Notably, both α(2-3,6,8,9)
neuraminidase A or α(2-3) neuraminidase treatments significantly increased cell adhesion onto full-length
Gal-8-coated surfaces, compared with untreated or to ALCAM-silenced cells. Thus, treatment with neurami-
nidases unmasks Gal-8 ligands, as reported by others [29], and favors Gal-8-mediated cell adhesion [45]. To
understand the relevance of sialylated glycans in Gal-8-induced cell adhesion, we recently analyzed the spe-
cific N-glycosylation profile of ALCAM as a Gal-8 ligand in MDA-MB-231 cells, and confirmed a high per-
centage of permissive structures with neutral terminal N-acetyllactosamine residues or α(2-3)-sialylated
structures. Notably, when digested with α(2-3,6,8,9) neuraminidase, a considerable increase in permissive
structures was obtained, as removal of α(2-6) sialylation unmasked N-acetyllactosamine residues. Even
though not all permissive N-glycans characterized in ALCAM may be exposed on the surface of these cells,
and Gal-8 induction of cell adhesion may also be mediated by other glycosylated ligands such as integrins
or CD44, Gal-8 interaction and induction of MDA-MB-231 cell adhesion does not require α
(2-3)-sialylation, and can also be mediated by neutral glycans [45]. Interestingly, Renard et al. [60] recently
showed that Gal-8 acts in concert with endophilin-A3 to control clathrin-independent endocytosis of
ALCAM/CD166.
Case study 5: Gal-8 domains and their different roles on immune cells and
platelets
When evaluating neutrophil adhesion, Gal-8C seems to have a primordial role, since mutant full-length Gal-8
lacking the carbohydrate-binding activity of N-terminal CRD (Gal-8 R69H) retained neutrophil adhesion activ-
ity, while inactivation of the C-terminal domain (Gal-8 R233H) abolished this function [61]. Conversely, plate-
let adhesion was promoted by isolated Gal-8N and protein chimera Gal-8NN, as well as full-length Gal-8. All
of them generated aggregation and secretion of dense and alpha granules, highlighting the central role of the
N-terminal domain for this biological function [62].
In T cells, Gal-8NN and Gal-8CC homodimers, but not isolated N- or C-terminal domains, were able to
induce proliferation; however, single domains induced T-cell co-stimulation, suggesting that tandem-repeat
structure is essential only for the proliferative effect. In both cases, CC chimeras displayed higher activity than
WT Gal-8, indicating that the C-CRD was the main domain involved, as was further supported by the strong
inhibition of proliferation and co-stimulation in the presence of blood group B antigen [63].
© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society10
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Perspectives
• Importance of Gal-8 functional and structural studies: Gal-8 has been intensively studied given
its abundance in several carcinomas and its broad pro-tumorigenic effects, including cell
adhesion and migration, as well as angiogenesis and lymphangiogenesis. Among members of
the galectin family, structure-activity analysis of tandem-repeat type galectins has remained
challenging due to difficulties in their crystallization, particularly as full-length galectins. Thus,
structural studies on apo galectins and their complexes with specific oligosaccharides is
essential for understanding structure–function relationships and delving into their biological
roles and evolutionary advantages.
• Summary of current knowledge on Gal-8 and its CRDs: Gal-8 CRDs differ noticeably in
their carbohydrate specificity. However, studies on the full-length lectin show that Gal-8
recognizes and binds a broader scope of ligands than its separate CRDs. In solution
studies, both domains seem to act independently of each other, exhibiting similar speci-
ficity and affinity as the isolated domains. Crystallographic studies unveiled critical resi-
dues mediating this differential affinity; however, when exploring the biological functions
of this lectin at the cell surface, Gal-8 has shown the ability to bind ligands recognized
by either CRD but also glycans of low affinity for either of them, indicating that, for this
tandem-repeat type galectin (and probably others), prediction of biological function by
each separate domain is limited. Although the reasons for this broader specificity still
remain unclear, linker flexibility and proper disposition of Gal-8 CRDs should not be
overlooked. Certain biological functions are mainly dependent on either CRD, while other
specific roles are only mediated by full-length Gal-8, probably as an evolutionary mech-
anism to preserve function independently of alterations in cellular glycosylation. Assay
temperature should be carefully considered in each experimental design: cell surface
binding experiments by flow cytometry are performed in the cold to avoid endocytosis,
while Gal-8 biological functions are studied at 37°C, a condition in which the lectin is
being endocytosed.
• Future directions: Gal-8-glycan specificity, as determined by biophysical studies, does not
always correlate with cellular binding assays, where results markedly vary within each cell
type, its glycome and the specific cell function analyzed. Therefore, studies are needed to elu-
cidate both the contribution of each Gal-8 CRD and the role of the full-length protein.
Moreover, other factors that could control cell binding, including dimerization at the cell
surface, have not been fully documented and need to be addressed.
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lactose; LacNAc, N-acetillactosamine; Lec1 cell, mutant CHO cell bearing a mutated Mgat1 gene (encoding β
(1-2)-N-acetylglucosaminyltransferase I); Lec2 cell, mutant CHO cell bearing a mutated CMP-sialic acid
transporter; Mgat, N-acetylglucosaminyltransferase gene; NDP52, nuclear domain 10 protein 52; Neu5Ac,
N-acetylneuraminic acid or sialic acid; NMR, nuclear magnetic resonance; PDB, protein data bank; poly-LacNAc,
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References
1 Barondes, S.H., Cooper, D.N., Gitt, M.A. and Leffler, H. (1994) Galectins. Structure and function of a large family of animal lectins. J. Biol. Chem. 269,
20807–20810 PMID: 8063692
2 Johannes, L., Jacob, R. and Leffler, H. (2018) Galectins at a glance. J. Cell Sci. 131, jcs208884 https://doi.org/10.1242/jcs.208884
3 Elola, M.T., Blidner, A.G., Ferragut, F., Bracalente, C. and Rabinovich, G.A. (2015) Assembly, organization and regulation of cell-surface receptors by
lectin–glycan complexes. Biochem. J. 469, 1–16 https://doi.org/10.1042/BJ20150461
4 Elola, M.T., Ferragut, F., Mendez-Huergo, S.P., Croci, D.O., Bracalente, C. and Rabinovich, G.A. (2018) Galectins: multitask signaling molecules linking
fibroblast, endothelial and immune cell programs in the tumor microenvironment. Cell. Immunol. 333, 34–45 https://doi.org/10.1016/j.cellimm.2018.03.
008
5 Elola, M.T., Wolfenstein-Todel, C., Troncoso, M.F., Vasta, G.R. and Rabinovich, G.A. (2007) Galectins: matricellular glycan-binding proteins linking cell
adhesion, migration, and survival. Cell Mol. Life Sci. 64, 1679–1700 https://doi.org/10.1007/s00018-007-7044-8
6 Cerliani, J.P., Blidner, A.G., Toscano, M.A., Croci, D.O. and Rabinovich, G.A. (2017) Translating the ‘sugar code’ into immune and vascular signaling
programs. Trends Biochem. Sci. 42, 255–273 https://doi.org/10.1016/j.tibs.2016.11.003
7 Girotti, M.R., Salatino, M., Dalotto-Moreno, T. and Rabinovich, G.A. (2019) Sweetening the hallmarks of cancer: galectins as multifunctional mediators of
tumor progression. J. Exp. Med. 217, e20182041 https://doi.org/10.1084/jem.20182041
8 Cummings, R.D., Liu, F.T. and Vasta, G.R. (2015) Galectins, In Essentials of Glycobiology (Varki, A., Cummings, R.D., Esko, J.D., Stanley, P., Hart, G.W.,
Aebi, M. et al., eds) Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press, Chapter 36, 1–14
9 Nabi, I.R., Shankar, J. and Dennis, J.W. (2015) The galectin lattice at a glance. J. Cell Sci. 128, 2213–2219 https://doi.org/10.1242/jcs.151159
10 Rabinovich, G.A. and Toscano, M.A. (2009) Turning ‘sweet’ on immunity: galectin–glycan interactions in immune tolerance and inflammation. Nat. Rev.
Immun. 9, 338–352 https://doi.org/10.1038/nri2536
11 Thiemann, S. and Baum, L.G. (2016) Galectins and immune responses–just how do they do those things they do? Annu. Rev. Immun. 34, 243–264
https://doi.org/10.1146/annurev-immunol-041015-055402
12 Dennis, J.W. and Brewer, C.F. (2013) Density-dependent lectin–glycan interactions as a paradigm for conditional regulation by posttranslational
modifications. Mol. Cell. Proteom. 12, 913–920 https://doi.org/10.1074/mcp.R112.026989
13 Lakshminarayan, R., Wunder, C., Becken, U., Howes, M.T., Benzing, C., Arumugam, S. et al. (2014) Galectin-3 drives glycosphingolipid-dependent
biogenesis of clathrin-independent carriers. Nat. Cell Biol. 16, 595–606 https://doi.org/10.1038/ncb2970
14 Johannes, L., Wunder, C. and Shafaq-Zadah, M. (2016) Glycolipids and lectins in endocytic uptake processes. J. Mol. Biol. 428, 4792–4818
https://doi.org/10.1016/j.jmb.2016.10.027
15 Salomonsson, E., Larumbe, A., Tejler, J., Tullberg, E., Rydberg, H., Sundin, A. et al. (2010) Monovalent interactions of galectin-1. Biochemistry 49,
9518–9532 https://doi.org/10.1021/bi1009584
16 Johannes, L. and Billet, A. (2020) Glycosylation and raft endocytosis in cancer. Cancer Metastasis Rev. https://doi.org/10.1007/s10555-020-09880-z
17 Bidon-Wagner, N. and Le Pennec, J.P. (2002) Human galectin-8 isoforms and cancer. Glycoconj J. 19, 557–563 https://doi.org/10.1023/B:GLYC.
0000014086.38343.98
18 Ahmed, H., Banerjee, P.P. and Vasta, G.R. (2007) Differential expression of galectins in normal, benign and malignant prostate epithelial cells: silencing
of galectin-3 expression in prostate cancer by its promoter methylation. Biochem. Biophys. Res. Commun. 358, 241–246 https://doi.org/10.1016/j.bbrc.
2007.04.114
19 Gopalkrishnan, R.V., Roberts, T., Tuli, S., Kang, D., Christiansen, K.A. and Fisher, P.B. (2000) Molecular characterization of prostate carcinoma tumor
antigen-1, PCTA-1, a human galectin-8 related gene. Oncogene 19, 4405–4416 https://doi.org/10.1038/sj.onc.1203767
20 Nishi, N., Itoh, A., Shoji, H., Miyanaka, H. and Nakamura, T. (2006) Galectin-8 and galectin-9 are novel substrates for thrombin. Glycobiology 16,
15C–20C https://doi.org/10.1093/glycob/cwl028
21 Troncoso, M.F., Ferragut, F., Bacigalupo, M.L., Cardenas Delgado, V.M., Nugnes, L.G., Gentilini, L. et al. (2014) Galectin-8: a matricellular lectin with
key roles in angiogenesis. Glycobiology 24, 907–914 https://doi.org/10.1093/glycob/cwu054
22 Waterhouse, A.M., Procter, J.B., Martin, D.M.A., Clamp, M. and Barton, G.J. (2009) Jalview version 2-a multiple sequence alignment editor and
analysis workbench. Bioinformatics 25, 1189–1191 https://doi.org/10.1093/bioinformatics/btp033
23 Ideo, H., Matsuzaka, T., Nonaka, T., Seko, A. and Yamashita, K. (2011) Galectin-8-N-domain recognition mechanism for sialylated and sulfated glycans.
J. Biol. Chem. 286, 11346–11355 https://doi.org/10.1074/jbc.M110.195925
24 Yoshida, H., Yamashita, S., Teraoka, M., Itoh, A., Nakakita, S., Nishi, N. et al. (2012) X-ray structure of a protease-resistant mutant form of human
galectin-8 with two carbohydrate recognition domains. FEBS J. 279, 3937–3951 https://doi.org/10.1111/j.1742-4658.2012.08753.x
© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society12







soctrans/article-pdf/doi/10.1042/BST20200311/886460/bst-2020-0311.pdf by guest on 29 June 2020
25 Zick, Y., Eisenstein, M., Goren, R.A., Hadari, Y.R., Levy, Y. and Ronen, D. (2002) Role of galectin-8 as a modulator of cell adhesion and cell growth.
Glycoconj J. 19, 517–526 https://doi.org/10.1023/B:GLYC.0000014081.55445.af
26 Hirabayashi, J., Hashidate, T., Arata, Y., Nishi, N., Nakamura, T., Hirashima, M. et al. (2002) Oligosaccharide specificity of galectins: a search by frontal
affinity chromatography. Biochim. Biophys. Acta 1572, 232–254 https://doi.org/10.1016/S0304-4165(02)00311-2
27 Ideo, H., Seko, A., Ishizuka, I. and Yamashita, K. (2003) The N-terminal carbohydrate recognition domain of galectin-8 recognizes specific
glycosphingolipids with high affinity. Glycobiology 13, 713–723 https://doi.org/10.1093/glycob/cwg094
28 Patnaik, S.K., Potvin, B., Carlsson, S., Sturm, D., Leffler, H. and Stanley, P. (2006) Complex N-glycans are the major ligands for galectin-1, -3, and -8
on Chinese hamster ovary cells. Glycobiology 16, 305–317 https://doi.org/10.1093/glycob/cwj063
29 Carlsson, S., Oberg, C.T., Carlsson, M.C., Sundin, A., Nilsson, U.J., Smith, D. et al. (2007) Affinity of galectin-8 and its carbohydrate recognition
domains for ligands in solution and at the cell surface. Glycobiology 17, 663–676 https://doi.org/10.1093/glycob/cwm026
30 Stowell, S.R., Arthur, C.M., Slanina, K.A., Horton, J.R., Smith, D.F. and Cummings, R.D. (2008) Dimeric galectin-8 induces phosphatidylserine exposure
in leukocytes through polylactosamine recognition by the C-terminal domain. J. Biol. Chem. 283, 20547–20559 https://doi.org/10.1074/jbc.
M802495200
31 Kumar, S., Frank, M. and Schwartz-Albiez, R. (2013) Understanding the specificity of human galectin-8C domain interactions with its glycan ligands
based on molecular dynamics simulations. PLoS One 8, e59761 https://doi.org/10.1371/journal.pone.0059761
32 Maller, S.M., Cagnoni, A.J., Bannoud, N., Sigaut, L., Pérez Sáez, J.M., Pietrasanta, L.I. et al. (2020) An adipose tissue galectin controls endothelial cell
function via preferential recognition of 3-fucosylated glycans. FASEB J. 34, 735–753 https://doi.org/10.1096/fj.201901817R
33 Yoshida, H., Teraoka, M., Nishi, N., Nakakita, S., Nakamura, T., Hirashima, M. et al. (2010) X-ray structures of human galectin-9 C-terminal domain in
complexes with a biantennary oligosaccharide and sialyllactose. J. Biol. Chem. 285, 36969–36976 https://doi.org/10.1074/jbc.M110.163402
34 Salomonsson, E., Carlsson, M.C., Osla, V., Hendus-Altenburger, R., Kahl-Knutson, B., Öberg, C.T., et al. (2010) Mutational tuning of galectin-3
specificity and biological function. J. Biol. Chem. 285, 35079–35091 https://doi.org/10.1074/jbc.M109.098160
35 Li, S., Wandel, M.P., Li, F., Liu, Z., He, C., Wu, J. et al. (2013) Sterical hindrance promotes selectivity of the autophagy cargo receptor NDP52 for the
danger receptor galectin-8 in antibacterial autophagy. Sci. Signal. 6, ra9 https://doi.org/10.1126/scisignal.6306er9
36 Kim, B.-W., Hong, S.B., Kim, J.H., Kwon, D.H. and Song, H.K. (2013) Structural basis for recognition of autophagic receptor NDP52 by the sugar
receptor galectin-8. Nat. Commun. 4, 1613 https://doi.org/10.1038/ncomms2606
37 Hadari, Y.R., Arbel-Goren, R., Levy, Y., Amsterdam, A., Alon, R., Zakut, R. et al. (2000) Galectin-8 binding to integrins inhibits cell adhesion and
induces apoptosis. J. Cell Sci. 113, 2385–2397 PMID:10852818
38 Levy, Y., Arbel-Goren, R., Hadari, Y.R., Eshhar, S., Ronen, D., Elhanany, E. et al. (2001) Galectin-8 functions as a matricellular modulator of cell
adhesion. J. Biol. Chem. 276, 31285–31295 https://doi.org/10.1074/jbc.M100340200
39 Delgado, V.M., Nugnes, L.G., Colombo, L.L., Troncoso, M.F., Fernandez, M.M., Malchiodi, E.L. et al. (2011) Modulation of endothelial cell migration and
angiogenesis: a novel function for the “tandem-repeat” lectin galectin-8. FASEB J. 25, 242–254 https://doi.org/10.1096/fj.09-144907
40 Chen, W.-S., Cao, Z., Sugaya, S., Lopez, M.J., Sendra, V.G., Laver, N. et al. (2016) Pathological lymphangiogenesis is modulated by
galectin-8-dependent crosstalk between podoplanin and integrin-associated VEGFR-3. Nat. Commun. 7, 11302 https://doi.org/10.1038/ncomms11302
41 Elola, M.T., Ferragut, F., Cardenas Delgado, V.M., Nugnes, L.G., Gentilini, L., Laderach, D. et al. (2014) Expression, localization and function of
galectin-8, a tandem-repeat lectin, in human tumors. Histol. Histopathol. 29, 1093–1105 https://doi.org/10.14670/HH-29.1093
42 Vinik, Y., Shatz-Azoulay, H. and Zick, Y. (2018) Molecular mechanisms underlying the role of galectin-8 as a regulator of cancer growth and metastasis.
Trends Glycosci. Glycotech. 30, SE119–SE128 https://doi.org/10.4052/tigg.1742.1SE
43 Oyanadel, C., Holmes, C., Pardo, E., Retamal, C., Shaughnessy, R., Smith, P. et al. (2018) Galectin-8 induces partial epithelial–mesenchymal transition
with invasive tumorigenic capabilities involving a FAK/EGFR/proteasome pathway in Madin–Darby canine kidney cells. Mol. Biol. Cell 29, 557–574
https://doi.org/10.1091/mbc.E16-05-0301
44 Gentilini, L.D., Jaworski, F.M., Tiraboschi, C., González Pérez, I., Kotler, M.L., Chauchereau, A. et al. (2017) Stable and high expression of Galectin-8
tightly controls metastatic progression of prostate cancer. Oncotarget 8, 44654–44668 https://doi.org/10.18632/oncotarget.17963
45 Ferragut, F., Cagnoni, A.J., Colombo, L.L., Sanchez Terrero, C., Wolfenstein-Todel, C., Troncoso, M.F. et al. (2019) Dual knockdown of galectin-8 and
its glycosylated ligand, the activated leukocyte cell adhesion molecule (ALCAM/CD166), synergistically delays in vivo breast cancer growth. Biochim.
Biophys. Acta Mol. Cell Res. 1866, 1338–1352 https://doi.org/10.1016/j.bbamcr.2019.03.010
46 Chen, C., Duckworth, C.A., Fu, B., Pritchard, D.M., Rhodes, J.M. and Yu, L.G. (2014) Circulating galectins -2, -4 and -8 in cancer patients make
important contributions to the increased circulation of several cytokines and chemokines that promote angiogenesis and metastasis. Br. J. Cancer 110,
741–752 https://doi.org/10.1038/bjc.2013.793
47 Barrow, H., Guo, X., Wandall, H.H., Pedersen, J.W., Fu, B., Zhao, Q. et al. (2011) Serum galectin-2, -4, and -8 are greatly increased in colon and
breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clin. Cancer Res. 17, 7035–7046 https://doi.org/10.1158/
1078-0432.CCR-11-1462
48 Tribulatti, M.V., Carabelli, J., Prato, C.A. and Campetella, O. (2019) Galectin-8 in the onset of the immune response and inflammation. Glycobiology 30,
134–142 https://doi.org/10.1093/glycob/cwz077
49 Tribulatti, M.V., Cattaneo, V., Hellman, U., Mucci, J. and Campetella, O. (2009) Galectin-8 provides costimulatory and proliferative signals to T
lymphocytes. J. Leukoc Biol. 86, 371–380 https://doi.org/10.1189/jlb.0908529
50 Boyle, K.B. and Randow, F. (2013) The role of ‘eat-me’ signals and autophagy cargo receptors in innate immunity. Curr. Opin. Microbiol. 16, 339–348
https://doi.org/10.1016/j.mib.2013.03.010
51 Kwon, D.H. and Song, H.K.A. (2018) Structural view of xenophagy, a battle between host and microbes. Mol. Cells 41, 27–34 https://doi.org/10.
14348/molcells.2018.2274
52 Meinohl, C., Barnard, S.J., Fritz-Wolf, K., Unger, M., Porr, A., Heipel, M. et al. (2020) Galectin-8 binds to the farnesylated C-terminus of K-Ras4B and
modifies Ras/ERK signaling and migration in pancreatic and lung carcinoma cells. Cancers (Basel) 12, 30 https://doi.org/10.3390/cancers12010030
53 Nielsen, M.I., Stegmayr, J., Grant, O.C., Yang, Z., Nilsson, U.J., Boos, I. et al. (2018) Galectin binding to cells and glycoproteins with genetically
modified glycosylation reveals galectin–glycan specificities in a natural context. J. Biol. Chem. 293, 20249–20262 https://doi.org/10.1074/jbc.RA118.
004636
© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society 13







soctrans/article-pdf/doi/10.1042/BST20200311/886460/bst-2020-0311.pdf by guest on 29 June 2020
54 Ludwig, A.K., Michalak, M., Shilova, N., Andre, S., Kaltner, H., Bovin, N.V. et al. (2017) Studying the structural significance of galectin design by playing
a modular puzzle: homodimer generation from human tandem-repeat-type (heterodimeric) galectin-8 by domain shuffling. Molecules 22, 1572
https://doi.org/10.3390/molecules22091572
55 Raymond, C., Robotham, A., Spearman, M., Butler, M., Kelly, J. and Durocher, Y. (2015) Production of α2,6-sialylated IgG1 in CHO cells. MAbs 7,
571–583 https://doi.org/10.1080/19420862.2015.1029215
56 Carlsson, S., Carlsson, M.C. and Leffler, H. (2007) Intracellular sorting of galectin-8 based on carbohydrate fine specificity. Glycobiology 17, 906–912
https://doi.org/10.1093/glycob/cwm059
57 Hong, M.H., Lin, W.H., Weng, I.C., Hung, Y.H., Chen, H.L., Chen, H.Y. et al. (2019) Glycobiology 30, 49–57 https://doi.org/10.1093/glycob/cwz075
58 Levy, Y., Auslender, S., Eisenstein, M., Vidavski, R.R., Ronen, D., Bershadsky, A.D. et al. (2006) It depends on the hinge: a structure-functional analysis
of galectin-8, a tandem-repeat type lectin. Glycobiology 16, 463–476 https://doi.org/10.1093/glycob/cwj097
59 Fernandez, M.M., Ferragut, F., Cardenas Delgado, V.M., Bracalente, C., Bravo, A.I., Cagnoni, A.J. et al. (2016) Glycosylation-dependent binding of
galectin-8 to activated leukocyte cell adhesion molecule (ALCAM/CD166) promotes its surface segregation on breast cancer cells. Biochim. Biophys.
Acta 1860, 2255–2268 https://doi.org/10.1016/j.bbagen.2016.04.019
60 Renard, H.F., Tyckaert, F., Lo Giudice, C., Hirsch, T., Valades-Cruz, C.A., Lemaigre, C. et al. (2020) Endophilin A3 and galectin-8 control the
clatrin-independent endocytosis of CD166. Nat. Commun. 11, 1457 https://doi.org/10.1038/s41467-020-15303-y
61 Nishi, N., Shoji, H., Seki, M., Itoh, A., Miyanaka, H., Yuube, K. et al. (2003) Galectin-8 modulates neutrophil function via interaction with integrin
alphaM. Glycobiology 13, 755–763 https://doi.org/10.1093/glycob/cwg102
62 Romaniuk, M.A., Tribulatti, M.V., Cattaneo, V., Lapponi, M.J., Molinas, F.C., Campetella, O. et al. (2010) Human platelets express and are activated by
galectin-8. Biochem. J. 432, 535–547 https://doi.org/10.1042/BJ20100538
63 Cattaneo, V., Tribulatti, M.V. and Campetella, O. (2011) Galectin-8 tandem-repeat structure is essential for T-cell proliferation but not for co-stimulation.
Biochem. J. 434, 153–160 https://doi.org/10.1042/BJ20101691
© 2020 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society14







soctrans/article-pdf/doi/10.1042/BST20200311/886460/bst-2020-0311.pdf by guest on 29 June 2020
